From Surf Wiki (app.surf) — the open knowledge base

Olanzapine/fluoxetine

Antidepressant medication

| Drugs.com =

Olanzapine/fluoxetine (trade name Symbyax, created by Eli Lilly and Company) is a fixed-dose combination medication containing olanzapine (Zyprexa), an atypical antipsychotic, and fluoxetine (Prozac), a selective serotonin reuptake inhibitor (SSRI). Olanzapine/fluoxetine is primarily used to treat the depressive episodes of bipolar I disorder as well as treatment-resistant depression.

Medical uses

Olanzapine/fluoxetine was approved by the U.S. Food and Drug Administration (FDA) to treat the depressive episodes of bipolar I disorder in 2003. In 2009, it was granted approval for the treatment of treatment-resistant depression.

Olanzapine/fluoxetine, or other antidepressant/antipsychotic combinations, are sometimes prescribed off-label for anxiety disorders, eating disorders, obsessive–compulsive disorder (OCD), and posttraumatic stress disorder (PTSD).

Side effects

Possible side effects of olanzapine/fluoxetine include all those of the two component drugs: olanzapine (side effects) and fluoxetine (side effects). Common side effects include suicidal thoughts, increased appetite, weight gain, drowsiness, fatigue, dry mouth, swelling, tremor, blurred vision, and difficulty concentrating.

Olanzapine/fluoxetine could produce a severe allergic reaction and should not be used if the patient has previously experienced an allergic reaction to either fluoxetine or olanzapine.

Olanzapine is correlated with an increase in blood sugar. Patients with diabetes, or those at risk for developing it, require careful monitoring.

In rare cases, olanzapine/fluoxetine may cause neuroleptic malignant syndrome.

Like other SSRIs, olanzapine/fluoxetine carries a boxed warning stating that it could increase the risk of suicidal thoughts and behaviors in patients aged 24 and under. The warning also states that olanzapine/fluoxetine may increase the risk of death in elderly patients with dementia-related psychosis.

References

"Tratamento medicamentoso dos transtornos bipolares - Transtornos psiquiátricos".
(21 April 2020). "Symbyax- olanzapine and fluoxetine hydrochloride capsule".
(October 2009). "Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis". The Journal of Clinical Psychiatry.
Grohol, J.. "FDA Approves Symbyax for Treatment Resistant Depression". Psych Central Blog.
(2003). "The role of atypical antipsychotics in bipolar depression and anxiety disorders". Bipolar Disorders.
(October 2003). "Towards the pharmacotherapy of eating disorders". Expert Opinion on Pharmacotherapy.
(July 2000). "Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder". The Journal of Clinical Psychiatry.
(October 2002). "Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study". The American Journal of Psychiatry.
"Symbyax". Drugs.com.

Info: Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

dopamine-antagonists muscarinic-antagonists selective-serotonin-reuptake-inhibitors serotonin-receptor-antagonists atypical-antipsychotics antidepressants drugs-developed-by-eli-lilly-and-company mood-stabilizers combination-psychiatric-drugs

Want to explore this topic further?

Ask Mako anything about Olanzapine/fluoxetine — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report